ORCA Therapeutics Strengthens Patent Portfolio with New US Patent Grant

Amsterdam, Netherlands – January 2025

ORCA Therapeutics B.V., a Dutch biopharmaceutical company pioneering innovative oncolytic neo-adjuvant immunotherapies for cancer treatment, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent related to novel oncolytic adenovirus technology. This patent further strengthens ORCA’s intellectual property portfolio as the company continues to advance its lead product, ORCA-010, through clinical development.

The newly granted patent covers innovative approaches in oncolytic virus design, specifically relating to GSK3β incorporation. This technology represents one of several approaches ORCA is exploring to further advance the field of oncolytic neo-adjuvant immunotherapies.

“This patent grant adds to our robust intellectual property portfolio as we continue to focus on the clinical development of our lead product, ORCA-010,” said Dr. Wenliang Dong, Chief Executive Officer at ORCA Therapeutics. “Building a strong IP position supports our mission to develop innovative therapeutic solutions for cancer patients.”

This announcement follows the recent recognition of ORCA’s research at ESMO IO 2024, where Professor Tanja de Gruijl’s presentation on ORCA-010 was selected as a scientific highlight of the conference by the Society for Immunotherapy of Cancer (SITC).

About ORCA-010

ORCA-010 is a state-of-the-art oncolytic adenovirus therapy designed for enhanced tumor killing capabilities, while modifying the tumor microenvironment and inducing anti-tumor immune responses. Our Phase I/IIA trial in treatment-naïve, early-stage prostate cancer patients demonstrates that ORCA-010 can induce long-term immunological activation of the tumor microenvironment and induce systemic anti-tumor immune responses, supporting ORCA-010’s continued investigation as a potential treatment approach for cancer.

About ORCA Therapeutics BV

ORCA Therapeutics BV is a leader in potent neo-adjuvant immuno-oncology therapeutics, specializing in oncolytic viruses and innovative gene therapy approaches. The company is dedicated to translating cutting-edge scientific discoveries into effective therapeutic solutions, addressing unmet medical needs and improving patient outcomes globally.

For more information about our mission and ongoing projects, visit www.orca-therapeutics.com

Media Contact

Dr. Wenliang Dong, Ph.D., MBA
CEO, ORCA Therapeutics BV
Email: info@orca-therapeutics.com
Website: www.orca-therapeutics.com